Lonza to build large-scale fill & finish facility in Switzerland

The new facility will be delivered through an investment of approximately CHF 500 million and is expected to be completed in 2026

NHA announces successful onboarding of 1 lakh+ healthcare facilities

It includes both public and private health facilities including hospitals, clinics, diagnostic laboratories, and imaging centers

Wacker to expand mRNA-based actives capacity at Halle, Germany

Company is investing more than €100 million in the expansion of the Halle site

Boehringer Ingelheim, Evotec and bioMérieux forms JV Aurobac to fight antimicrobial resistance

The JV is funded by Boehringer Ingelheim as lead investor with 30 million EUR and by Evotec and bioMérieux with 5 million EUR each.

AMPEL BioSolutions' predicts drug options with RNA analytics & machine learning

Apollo Hospitals integrates cardiovascular risk tool with ConnectedLife digital wellness solutions

The AICVD tool can predict the risk of cardiovascular disease.

50% of heart attacks now happens in Indians below 50 years: says Expert

Younger Indians have a 10 times higher rate of heart attack

Pfizer to achieve net-zero standard by 2040

Pfizer aims to achieve net-zero targets ten years earlier than the expectations of the Net-Zero Standard

Lonza to invest 500 mn in commercial drug product fill & finish facility

The investment will enable the company to provide customers with a complete and integrated end-to-end solution

Biosynth Carbosynth expands peptide offering with acquisition of Pepscan

Addition of Pepscan with its peptide discovery, lead optimization and GMP manufacturing capabilities provides end-to-end offering to Biosynth Carbosynth’s peptide customers.